Skip to main content

Table 2 The 1-year combinations of classes of medication prescribed to the 8798 patients on PRT

From: High oral corticosteroid exposure and overuse of short-acting beta-2-agonists were associated with insufficient prescribing of controller medication: a nationwide electronic prescribing and dispensing database analysis

Maintenance treatment prescribed PRT with high OCS exposure (n = 186) PRT
n % n %
ICS + LABA 61 32.8 3113 35.4
ICS + LABA + LAMA 46 24.7 1008 11.5
ICS + LTRA + LABA + LAMA 21 11.3 355 4.0
ICS + LABA + LTRA 15 8.1 1204 13.7
LABA + LAMA 13 7.0 635 7.2
ICS monotherapy 8 4.3 310 3.5
LTRA monotherapy 6 3.2 916 10.4
LABA monotherapy 5 2.7 340 3.9
ICS + LAMA 3 1.6 143 1.6
LAMA monotherapy 3 1.6 476 5.4
ICS + LTRA 2 1.1 126 1.4
LTRA + LABA 1 0.5 50 0.6
LTRA + LAMA 1 0.5 41 0.5
ICS + LTRA + LAMA 1 0.5 22 0.3
LTRA + LABA + LAMA 0 0.0 59 0.7
  1. PRT persistent respiratory treatment, SABA short-acting beta2 agonist, OCS oral corticosteroids, ICS inhaled corticosteroids, LABA long-acting beta2 agonists, LTRA leukotriene receptors antagonists, LAMA long-acting muscarinic antagonist